Skip to main content

Human Solute Carriers

Edited by:
Professor Andy Tao Yin Lau, PhD, Shantou University Medical College, China
Professor Yasumasa Kato, MedScD, PhD, Ohu University School of Dentistry, Japan

Submission Status: Closed

This collection is no longer accepting submissions

Cancer Cell International is calling for submissions to our Collection on 'Human Solute Carriers.'

Human Solute Carriers have a great potential as therapeutic targets in cancer as their dysregulation has shown to play a critical role in various aspects of oncogenesis and cancer progression. 

  1. SLC25A17, a peroxisomal solute carrier, has been implicated in various physiological and pathological processes. However, its precise roles and underlying mechanisms in triple-negative breast cancer (TNBC) rem...

    Authors: Haiting Zhou, Jiahao Li, Yi He, Xiaohui Xia, Junxia Liu and Huihua Xiong
    Citation: Cancer Cell International 2024 24:85
  2. Disulfidptosis is a recently proposed novel cell death mode in which cells with high SLC7A11 expression induce disulfide stress and cell death in response to glucose deficiency. The purpose of the research was to...

    Authors: Leqi Zhong, Wuguang Chang, Bin Luo, Wuyou Gao, Huanhuan He, Mouxiang Fang, Hongmu Li, Zhesheng Wen and Youfang Chen
    Citation: Cancer Cell International 2024 24:2

About the collection

Cancer Cell International is calling for submissions to our Collection on 'Human Solute Carriers.'

The Human Solute Carriers (SLCs) constitute over 400 members organized into 66 families, yet, they are currently the least studied or neglected group of membrane transporters in humans. It has been shown that dysregulation of SLCs could play a critical role in various aspects of oncogenesis and cancer progression, therefore, SLCs could have great potential as disease therapeutic targets. 

In this collection, we welcome original articles on a range of topics including but not limited to the role of SLCs in cancer cell survival, growth, and metastasis; SLCs as diagnostic biomarkers or therapeutic targets; and the development of novel strategies to modulate SLCs function in cancer therapy. 

Image credit: © Steven /

Submission Guidelines

Back to top

This Collection welcomes submissions of Review and original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Human Solute Carriers " from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.